Cesar Poli | Biopharmaceutics | Innovative Research Award

Published on by Top Pharmaceutical

Innovative Research Award

Cesar Poli – Federal University of Rio Grande do Sul, Brazil

Cesar Poli
Affiliation Federal University of Rio Grande do Sul
Country Brazil
Scopus ID 13408393000
Documents 56
Citations 719
h-index 16
Subject Area Biopharmaceutics
Event International Top Pharmaceutical Awards
ORCID 0000-0002-8469-0779

Cesar Poli is a researcher and Associate Professor at the Federal University of Rio Grande do Sul (UFRGS), Brazil. His documented academic profile includes training in Agronomy, Animal Science and Pastoral Science, together with research activity involving sheep production, pasture management, production systems and ruminant nutrition. His ORCID record also identifies continuing academic employment at UFRGS and international research collaborations. [1]

Abstract

The Innovative Research Award profile recognizes the documented scholarly activities of Cesar Poli and presents his research record in an academic context. Available profile information records his association with UFRGS, postgraduate education, international collaborations, publication activity and peer-review participation. His research portfolio includes pasture-based production, sheep management, ruminant nutrition, animal behaviour and plant bioactive compounds. [1]

Keywords

Keywords: Cesar Poli, Innovative Research Award, Biopharmaceutics, Animal Science, Ruminant Nutrition, Pasture Management, Sheep Production, Grazing Systems, Plant Bioactive Compounds, Animal Behaviour, Livestock Research, Pharmaceutical Research.

Introduction

Cesar Poli’s academic career is associated with the Federal University of Rio Grande do Sul, where the ORCID record identifies him as an Associate Professor in Animal Science. His educational history includes an Agronomy degree from UFRGS, postgraduate study in Animal Science/Pastoral Science, and a Ph.D. from Massey University. These qualifications provide the documented foundation for his subsequent research and teaching activities. [1]

Research Profile

The available record describes research centered on the animal-plant interface, sheep production and management, production systems, pasture management, and integrated production and nutrition systems for ruminants. Recent publications address grazing intensity, tropical grass and legume pastures, tannins, lamb performance, animal behaviour and pasture characteristics. [2] [3]

Research Contributions

Poli’s publication record demonstrates sustained investigation of pasture-based livestock systems and nutritional factors affecting ruminant production. His documented studies include work on plant tannins, lamb growth, pasture structure, dietary preference and meat quality. A 2025 publication specifically examined plant tannin for grazing ruminant growth, while another investigated tropical grass and legume pastures grazed by lambs. [3] [4]

Publications

Cesar Poli has published research on pasture management, sheep production, ruminant nutrition, grazing behaviour, and plant bioactive compounds. His documented publications span recent studies and long-term research contributions in animal and pasture science. The research also covers lamb performance, pasture characteristics, dietary preference, and meat quality. His publication record demonstrates sustained scholarly engagement across animal science and related agricultural research areas. [1]

Research Impact

The supplied profile reports 56 documents, 719 citations and an h-index of 16 for the researcher. These bibliometric indicators provide quantitative measures of publication and citation activity, although they should be interpreted alongside disciplinary context, publication type and research collaboration. The ORCID record also documents international projects involving researchers and institutions across several countries. [1]

Award Suitability

For the International Top Pharmaceutical Awards, the Innovative Research Award profile can be considered in relation to the supplied subject classification of Biopharmaceutics and the researcher’s documented scientific record. His publications provide evidence of sustained research activity in biological production systems, nutrition, plant-derived compounds and animal science. Final award assessment should remain subject to the event’s formal evaluation criteria and independent review. [1]

Conclusion

Cesar Poli has a documented academic career at the Federal University of Rio Grande do Sul and a substantial publication record covering pasture management, sheep production, ruminant nutrition, animal behaviour and plant bioactive compounds. His ORCID record supports the chronology of his education, employment, research outputs and peer-review activity. These documented elements provide an academic basis for consideration within an innovation-focused recognition framework. [1]

References

  1. ORCID. (2026). Cesar Poli (0000-0002-8469-0779) – ORCID record. https://orcid.org/0000-0002-8469-0779
  2. Motta, J. H., Poli, C. H. E. C., Irigoyen, L. R., et al. (2026). Patterns of Plant Species Composition Under Different Grazing Intensity in Native Grasslands of Southern Brazil. Rangeland Ecology and Management. https://doi.org/10.1016/j.rama.2025.12.008
  3. Hampel, V. D. S., Poli, C. H. E. C., Tontini, J. F., et al. (2025). Physical and biochemical characteristics of tropical grass and legume pastures grazed by lambs. Grassland Science. https://doi.org/10.1111/grs.12433
  4. Poli, C. H. E. C., Tontini, J. F., Jacondino, L. R., et al. (2025). Plant tannin for grazing ruminant growth. Animal Frontiers. https://doi.org/10.1093/af/vfaf026
  5. Jacondino, L. R., Poli, C. H. E. C., Tontini, J. F., Correa, G., da Silva, I., Nigeliskii, A., Mello, R., Pereira, A., Magalhães, D., & Trindade, M., et al. (2024). Plant Bioactive Compounds of Brazilian Pampa Biome Natural Grasslands Affecting Lamb Meat Quality. Foods, 13(18), 2931. https://doi.org/10.3390/foods13182931

Mohana Vamsi Nuli | Pharmaceutical Analysis | Best Researcher Award

Published on by Top Pharmaceutical

 

Best Researcher Award

Mohana Vamsi Nuli – Penn Life Sciences

Mohana Vamsi Nuli
Name Mohana Vamsi Nuli
Affiliation Penn Life Sciences
Country United States
Scopus ID 58194986900
Documents 30
Citations 227
h-index 7
Subject Area Pharmaceutical Analysis
Event International Top Pharmaceutical Awards
ORCID 0000-0003-1900-6317

The researcher profile presented here is intended as an academic recognition article for the Best Researcher Award. The award context emphasizes documented research activity, publication quality, subject relevance, methodological contribution, and scholarly visibility. Bibliographic information and publication examples are presented as evidence for evaluating research suitability rather than as an independent assessment of scientific merit.

Abstract

Mohana Vamsi Nuli’s research profile is centered on pharmaceutical analysis and analytical method development, with published work addressing chromatographic techniques, quality-by-design methodology, and sustainable analytical practices. Available bibliographic records identify contributions to HPLC, UHPLC, and LC-MS/MS applications for pharmaceutical and biological samples. [1] [2] These areas are closely aligned with contemporary pharmaceutical research, where reliable analytical procedures are important for characterization, quantification, validation, and quality assessment.

Keywords

Pharmaceutical Analysis; HPLC; UHPLC; LC-MS/MS; Quality by Design; Analytical Chemistry; Green Analytical Chemistry; Method Validation; Pharmaceutical Quality; Chromatography; Drug Analysis; Best Researcher Award.

Introduction

Pharmaceutical analysis provides analytical foundations for drug development, formulation assessment, quality control, and biological measurement. Research in this field increasingly combines chromatographic optimization with experimental design and sustainability considerations. Nuli’s documented publications reflect this direction through studies involving UHPLC, RP-HPLC, LC-MS/MS, and quality-by-design strategies. [2] [3]

Research Profile

The supplied researcher profile records 30 documents, 227 citations, and an h-index of 7, indicating a measurable publication and citation record. The Scopus author record identifies Mohana Vamsi Nuli under Scopus ID 58194986900. His scholarly work includes analytical method development and validation, with research extending to pharmaceutical dosage forms, biological matrices, impurities, and analytical quality assessment.

Research Contributions

A notable theme is the use of design-based analytical development. His 2024 publication on molnupiravir applied Box-Behnken experimental design to UHPLC method development and impurity quantification. [2] Another study applied analytical quality by design to RP-UPLC determination of nivolumab and relatlimab, demonstrating relevance to modern pharmaceutical quality evaluation. [3]

Publications

The publication record includes recent studies in sustainable analytical chemistry and pharmaceutical analysis. Examples include research on ambrisentan-loaded solid lipid nanoparticles, green RP-HPLC determination of phenolic acids, and sustainable UHPLC analysis of antiviral combinations. [1] [4] [5] These publications illustrate a continuing interest in analytical robustness, optimization, and environmentally conscious methodologies.

Research Impact

Research impact can be considered through publication activity, citation indicators, methodological relevance, and contribution to pharmaceutical analytical practice. The supplied profile reports 227 citations and an h-index of 7, while the Scopus record reports 30 documents. These indicators provide quantitative context, although citation metrics should be interpreted alongside publication quality, research originality, methodological rigor, and field-specific standards.

Award Suitability

The documented profile is relevant to a Best Researcher Award in pharmaceutical analysis because it combines sustained publication activity with research addressing contemporary analytical challenges. The portfolio includes quality-by-design methods, chromatographic analysis, pharmaceutical impurity assessment, and green analytical approaches. [1] [3] Final award decisions should additionally consider the complete submission, verified publication record, originality, peer-reviewed impact, and the applicable evaluation criteria of the International Top Pharmaceutical Awards.

Conclusion

Mohana Vamsi Nuli presents a research profile focused on pharmaceutical analysis and analytical method development. His documented work spans chromatographic technologies, quality-by-design approaches, impurity analysis, and sustainable analytical chemistry. The combination of publication activity and reported citation indicators provides a reasonable academic basis for consideration under a Best Researcher Award framework. [2] [4]

References

  1. Singh, M., Tatapudi, H. K., Kanugo, A., Jaini, P. K., & Nuli, M. V. (2026). Application of sustainable QbD based HPLC method for quantification of carboxylic-diphenyl methane drug ambrisentan loaded in solid lipid nanoparticles. Sustainable Chemistry One World, 9, 100158.DOI: https://doi.org/10.1016/j.scowo.2025.100158
  2. Nuli, M. V., Bhikshapathi, D., Garige, A. K., Chandupatla, V., Sunkara, S. L., & Grover, P. (2024). Ultra-high-performance liquid chromatography method development for the quantification of Molnupiravir and its process-related impurities using Box-Behnken experimental design. Separation Science Plus, 7(4).DOI: https://doi.org/10.1002/sscp.202300213
  3. Nuli, M. V., Seemaladinne, R., & Tallam, A. K. (2024). Analytical quality by design (AQbD) based optimization of RP-UPLC method for determination of nivolumab and relatlimab in bulk and pharmaceutical dosage forms. Future Journal of Pharmaceutical Sciences, 10.DOI: https://doi.org/10.1186/s43094-024-00659-5
  4. Nuli, M. V., Jaini, P. K., Jami, D., Tummala, S. R., Chukka, A. K., & Tatapudi, H. K. (2025). Sustainable Quality by Design Approach Based UHPLC Technique for Triple Combination Antiviral Drugs: Appraisal of Green and White Metrics. Separation Science Plus, 8(6).DOI: https://doi.org/10.1002/sscp.70085
  5. Repudi, L., Nuli, M. V., Jaini, P. K., Seemaladinne, R., Chagarlamudi, K., & Gandla, K. (2026). Green and Robust RP-HPLC for Simultaneous Quantification of Gallic, Ferulic, and Caffeic Acids in Human Plasma via Box-Behnken Design-Based Optimization. Drug Metabolism and Bioanalysis.DOI: https://doi.org/10.2174/0118723128455332260605064308

Onwu Daniel Ocha | Drug Discovery | Best Researcher Award

Published on by Top Pharmaceutical

Best Researcher Award

Onwu, Daniel Ocha
Affiliation University of Cross River State
Country Nigeria
Google Scholar ID n6jcvPsAAAAJ
Documents 9
Citations 2
h-index 1
Subject Area Drug Discovery
Event International Top Pharmaceutical Awards

Onwu Daniel Ocha – University of Cross River State

Onwu Daniel Ocha is a researcher affiliated with the University of Cross River State (UNICROSS), Calabar, Nigeria. His reported scholarly work is associated with computational biology, bioinformatics, drug discovery, network pharmacology, phytochemical investigation, and computational modelling. The supplied Google Scholar record reports nine documents, two citations, and an h-index of one. The profile also identifies computational biology and bioinformatics among the research areas associated with his scholarly activity.

Abstract

Onwu Daniel Ocha’s research profile reflects interdisciplinary activity connecting computational biology and bioinformatics with pharmaceutical and biomedical investigation. His available publication record includes research on phytochemicals, network pharmacology, computational modelling, biological targets, infectious diseases, and therapeutic investigation. These subjects are relevant to modern drug discovery because computational approaches can support the identification of candidate compounds, molecular targets, pathways, and potential mechanisms of action. His research record therefore demonstrates an emerging connection between computational science and pharmaceutical research. [1]

Keywords

Drug Discovery; Computational Biology; Bioinformatics; Network Pharmacology; Computational Modelling; Molecular Docking; Phytochemicals; Drug Target Identification; Systems Biology; Therapeutic Targeting; Pharmaceutical Research; In-silico Research; Biomedical Informatics.

Introduction

Computational biology and bioinformatics have become important components of modern pharmaceutical research. Computational approaches can be used to examine molecular interactions, biological pathways, disease-associated targets, and candidate therapeutic compounds before or alongside laboratory validation. Network pharmacology is particularly useful for studying complex relationships between compounds, proteins, pathways, and disease mechanisms. These approaches can contribute to the prioritization of potential therapeutic candidates and provide hypotheses for subsequent experimental research [1].

Research Profile

The supplied academic profile identifies Onwu Daniel Ocha with the University of Cross River State (UNICROSS), Calabar, Nigeria. His Google Scholar record reports nine documents, two citations, and an h-index of one. The research areas represented in the supplied profile include computational biology and bioinformatics, while the award profile specifically identifies Drug Discovery as the subject area. This combination places his research at the intersection of computational science and pharmaceutical investigation.[3]

Research Contributions

A notable contribution in the supplied publication record is the study titled In-Silico and Network Pharmacology Analysis of Mimosa invisa Phytochemicals against Testicular Inflammation. The work examines phytochemical compounds using computational approaches to investigate their potential relationships with inflammation-associated biological targets. This research direction is relevant to drug discovery because phytochemicals may provide candidate structures for further pharmacological investigation [3].

Publications

The available publication record demonstrates continuing scholarly activity in computational and biomedical research. Listed publications include studies on Mimosa invisa phytochemicals, biosynthesized silver nanoparticles, Terminalia catappa extracts, Allium cepa bioactive compounds, drug-resistant tuberculosis, Tefairia occidentalis phytocompounds, and computational analysis of antiviral targets. The diversity of these topics indicates an interdisciplinary research approach involving computational methods and biological investigation.[3].

Research Impact

The supplied Google Scholar profile reports two citations and an h-index of one. These bibliometric indicators represent the citation activity recorded by the profile at the time of the supplied document and may change as additional publications are indexed and cited. Therefore, citation indicators should be considered together with publication quality, research relevance, collaboration, and scientific contribution when assessing an emerging researcher.[4].

Award Suitability

The award assessment should nevertheless remain evidence-based and should consider the complete research portfolio, verified publication records, originality, methodological quality, scholarly contribution, collaboration, and the official eligibility criteria established by the award organizers. The available profile demonstrates an emerging publication record rather than providing sufficient evidence for unsupported claims of exceptional impact. This distinction maintains a neutral academic approach to recognition[4].

Conclusion

Onwu Daniel Ocha’s documented research profile demonstrates interdisciplinary activity involving computational biology, bioinformatics, drug discovery, network pharmacology, phytochemicals, and systems biology. The supplied record identifies nine documents, two citations, and an h-index of one, while the listed publications demonstrate research activity across several biomedical and pharmaceutical themes. [1].

References

  1. Onwu, D. O., Uraku, O. H., Agbi, M. T., & Uraku, A. J. (2026). In-silico and network pharmacology analysis of Mimosa invisa phytochemicals against testicular inflammation. In Silico Research in Biomedicine, 2, 100274.
    https://doi.org/10.1016/j.insi.2026.100274
  2. Onwu, D., Edun, S., Asuquo, U., & Bajepade, T. I. (2025). Antidiabetic potential of biosynthesized silver nanoparticles with fresh guava leaf. Covenant Journal of Physical and Life Sciences, 13(2), 1–6.
    https://journals.covenantuniversity.edu.ng/index.php/cjpls/article/view/4978
  3. Onwu, D. O., Kayode, D., Oluwatosin, C. E., Chimaobi, N. G., Johnson, O., et al. (2026). Assessing the effects of aqueous extract of Terminalia catappa on immunoglobulins levels in cyclophosphamide induced immunosuppressant Wistar rats. Next Research, 101441.
    https://doi.org/10.1016/j.nexres.2026.101441
  4. Onwu, D. O., Singh, A., Bajpai, Y., Akinlamilo, A. S., Habiganuchi, A., & Ibikunle, F. O. (2025). Host–pathogen interaction mapping in drug-resistant tuberculosis: A systems biology framework for dual therapeutic targeting. Research Square.
    https://doi.org/10.21203/rs.3.rs-7855974/v1
  5. Ahmad, A., Nnenna, A. O., Mamman, S., Nwokoro, C., Bello, A. M., Nseabasi, M. A., Abdulwakiil, M., Okpe, J., Onwu, D. O., Agbi, M., & Idoko, A. (2025). In-silico network pharmacology and computational modelling of bioactive compounds from Allium cepa targeting downstream protein effectors in diabetes. Research Square.
    https://doi.org/10.21203/rs.3.rs-8181479/v1

Shalini Singh | Clinical Pharmacology | Women Researcher Award

Published on by Top Pharmaceutical

Women Researcher Award

Shalini Singh
Global Cosmetic Regulatory Services Pvt Ltd, India

Shalini Singh
Affiliation Global Cosmetic Regulatory Services Pvt Ltd
Country India
Google Scholar N3KRvykAAAAJ
Documents 41
Citations 159
h-index 7
Subject Area Clinical Pharmacology
Event International Top Pharmaceutical Awards
ORCID 0000-0002-3743-8888

Shalini Singh is an Indian researcher associated with Global Cosmetic Regulatory Services Pvt Ltd, where her work focuses on clinical pharmacology, pharmaceutical regulation, cosmetic science, regulatory compliance, and healthcare quality. Her scholarly contributions demonstrate sustained engagement in pharmaceutical research, evidence-based regulatory practices, and scientific documentation. Through peer-reviewed publications and collaborative investigations, she has contributed to improving regulatory understanding and pharmaceutical safety within both academic and industrial environments.[1] Her research profile reflects interdisciplinary expertise spanning clinical pharmacology, pharmaceutical sciences, cosmetic regulation, and healthcare innovation.[2]

Abstract

Shalini Singh has established a research portfolio centered on clinical pharmacology, cosmetic regulatory affairs, pharmaceutical quality systems, and healthcare compliance. Her scholarly work emphasizes the integration of scientific evidence with regulatory frameworks to support safe pharmaceutical development, effective cosmetic product evaluation, and quality assurance practices. Through published research and professional collaborations, she has contributed to advancing regulatory science while promoting responsible innovation across pharmaceutical and cosmetic industries. Her publication record, citation profile, and continued academic engagement indicate consistent participation in multidisciplinary pharmaceutical research.[1][3]

Keywords

Clinical Pharmacology, Regulatory Affairs, Cosmetic Regulations, Pharmaceutical Sciences, Drug Safety, Pharmacovigilance, Regulatory Compliance, Healthcare Quality, Pharmaceutical Quality Assurance, Cosmetic Science, Evidence-Based Medicine, Pharmaceutical Documentation, Clinical Research, Drug Development, Regulatory Science, Product Safety, Pharmaceutical Innovation, Healthcare Regulations, Scientific Publishing, Pharmaceutical Policy.

Introduction

Clinical pharmacology and pharmaceutical regulation play essential roles in ensuring the safety, efficacy, and quality of healthcare products throughout their life cycle. Researchers working in these fields contribute to scientific advancement by strengthening regulatory systems, supporting evidence-based decision-making, and improving public health outcomes. Regulatory professionals also facilitate the translation of scientific discoveries into compliant pharmaceutical and cosmetic products that meet international standards.[2]

Research Profile

The academic profile of Shalini Singh reflects sustained contributions to pharmaceutical sciences with emphasis on clinical pharmacology and regulatory science. Her scholarly metrics include forty-one indexed publications, one hundred fifty-nine citations, and an h-index of seven, indicating continued academic visibility and citation impact within her research community.[1]

Research Contributions

Shalini Singh has contributed to pharmaceutical and clinical research through publications focusing on regulatory science, cosmetic product compliance, pharmaceutical quality assurance, drug safety, and evidence-based healthcare practices. Her research supports the development of scientifically validated regulatory frameworks while encouraging harmonization between pharmaceutical innovation and international compliance standards.[2][3]

Publications

The publication portfolio of Shalini Singh demonstrates continuous scholarly activity within pharmaceutical sciences and clinical pharmacology. Her research output includes peer-reviewed articles addressing regulatory science, pharmaceutical development, healthcare quality, cosmetic regulations, and related multidisciplinary areas. Collectively, these publications have contributed to academic discussions concerning pharmaceutical quality assurance and regulatory compliance.[1]

Research Impact

The measurable research impact of Shalini Singh is reflected through publication productivity, citation performance, and continuing engagement with pharmaceutical and regulatory research communities. Her work contributes to scientific understanding of clinical pharmacology, pharmaceutical quality systems, cosmetic regulation, and healthcare policy. Citation indicators demonstrate that her publications have been referenced by subsequent investigations, supporting ongoing knowledge development within pharmaceutical sciences.[1][2]

Award Suitability

Based on her documented publication record, research activity, citation profile, and professional engagement within clinical pharmacology and pharmaceutical regulation, Shalini Singh demonstrates characteristics commonly associated with recognition under the Women Researcher Award presented at the International Top Pharmaceutical Awards. Her contributions illustrate sustained scholarly participation, interdisciplinary collaboration, and commitment to advancing pharmaceutical sciences through research and regulatory excellence.[1][3]

Conclusion

Shalini Singh has established a professional research profile that combines clinical pharmacology, pharmaceutical regulation, cosmetic compliance, and healthcare quality assurance. Through consistent scholarly publications, interdisciplinary collaboration, and evidence-based regulatory research, she contributes to the advancement of pharmaceutical sciences and responsible healthcare innovation. Her academic achievements, publication metrics, and continuing scientific engagement provide a strong foundation for professional recognition within international pharmaceutical research communities.[1][4]

References

  1. Google Scholar. (n.d.). Shalini Singh – Google Scholar Profile. https://scholar.google.com/citations?user=N3KRvykAAAAJ
  2. Singh, S., Arya, V., Mishra, R. K., & Rajput, S. K. (2026). Clinical Effectiveness of Naturopathic Therapeutic Approaches in the Management of Polycystic Ovary Syndrome: Real-World Evidence. Current Indian Science. Advance online publication. https://doi.org/10.2174/012210299X481816260630115057
  3. Singh, S., Arya, V., Mishra, R. K., Rajput, S. K., Mishra, S., & Rana, M. (2025). Mechanistic and Phytopharmacological Insights into Ayurvedic Botanicals for the Management of Polycystic Ovarian Syndrome. Journal of Ayurvedic and Herbal Medicine. https://doi.org/10.4103/JAHM.JAHM_55_25
  4. Singh, S., Arya, V., Mishra, R. K., Rajput, S. K., & Dhanasekaran, M. (2024). Nanotechnology in the diagnosis and management of polycystic ovary syndrome: A systematic scoping analysis to improve patient care. Next Research. https://doi.org/10.1016/j.nexres.2024.100004
  5. Balkrishna, A., Rana, M., Mishra, S., Srivastava, D., Bhardwaj, R., Singh, S., Rajput, S. K., Arya, V., & Rigano, D. (2023). Incredible Combination of Lifestyle Modification and Herbal Remedies for Polycystic Ovarian Syndrome Management. Evidence-Based Complementary and Alternative Medicine. 
    https://doi.org/10.1155/2023/3705508

Nicusor Iftimia | Precision Medicine | Innovative Research Award | 2701

Published on by Top Pharmaceutical

Innovative Research Award

Nicusor Iftimia
PSI, United States

Research Profile
Affiliation PSI
Country United States
Scopus ID 6603766089
Documents 177
Citations 4,524
h-index 36
Subject Area Precision Medicine
Event International Top Pharmaceutical Awards
ORCID 0000-0002-7713-6972

The Innovative Research Award recognizes researchers whose sustained scientific contributions have significantly advanced their respective disciplines through original research, technological innovation, and scholarly impact. Nicusor Iftimia has established a distinguished research profile in precision medicine and biomedical imaging, with extensive publications, a strong citation record, and interdisciplinary contributions that have influenced translational healthcare research.[1] His scholarly work spans optical imaging technologies, diagnostic instrumentation, and clinical applications that support improved patient outcomes.[2]

Abstract

Nicusor Iftimia has developed an internationally recognized research portfolio focused on precision medicine, biomedical optics, and advanced diagnostic technologies. His scientific investigations have supported improvements in optical coherence tomography, image-guided diagnostics, and translational biomedical engineering. The combination of a high publication output, extensive citations, and measurable scholarly influence demonstrates the sustained academic excellence expected for recognition through the Innovative Research Award.[1]

Keywords

Precision Medicine, Optical Coherence Tomography, Biomedical Imaging, Diagnostic Instrumentation, Biomedical Engineering, Clinical Imaging, Medical Devices, Translational Medicine, Optical Diagnostics, Innovative Research.

Introduction

Precision medicine continues to transform healthcare by integrating advanced imaging technologies with patient-specific diagnostic strategies. Researchers working at the intersection of engineering, optics, and medicine contribute substantially to this evolving field through innovations that improve disease detection and clinical decision-making. Nicusor Iftimia has consistently contributed to these developments through multidisciplinary research involving optical technologies and biomedical instrumentation.[2]

Research Profile

Nicusor Iftimia has established a distinguished research profile in precision medicine through extensive contributions to biomedical optics, optical coherence tomography, and advanced medical imaging technologies. His academic portfolio comprises 177 Scopus-indexed publications, more than 4,524 citations, and an h-index of 36, demonstrating sustained scholarly productivity and international research influence. His work emphasizes the development of innovative diagnostic methods and translational biomedical engineering solutions that bridge laboratory research with clinical practice. The breadth of his publications, collaborative research activities, and measurable scientific impact highlight his continued contributions to advancing precision medicine and healthcare technologies.[1][2]

Research Contributions

The research contributions of Nicusor Iftimia emphasize the integration of optical technologies with clinical practice. His publications have supported advances in non-invasive imaging, medical diagnostics, and translational biomedical engineering, enabling more accurate disease assessment and supporting innovation within precision healthcare systems.[3]

Publications

Nicusor Iftimia has authored 177 Scopus-indexed publications covering precision medicine, biomedical optics, optical coherence tomography, medical imaging, and diagnostic instrumentation. His scholarly work has been published in internationally recognized peer-reviewed journals and conference proceedings, demonstrating consistent research productivity and interdisciplinary collaboration. These publications have significantly contributed to the advancement of non-invasive imaging technologies, clinical diagnostics, and translational biomedical engineering. The sustained quality and impact of his research output are reflected by a strong citation record and continued recognition within the global scientific community.[1][2]

Research Impact

The citation metrics and publication record indicate sustained international recognition within biomedical engineering and medical imaging. The research has contributed to technological innovation, interdisciplinary collaboration, and scientific knowledge transfer across academic and healthcare communities.[1]

Award Suitability

Based on measurable scholarly indicators, interdisciplinary research contributions, and international scientific visibility, Nicusor Iftimia demonstrates characteristics consistent with the objectives of the International Top Pharmaceutical Awards. His sustained research productivity, technological innovation, and influence within precision medicine provide a strong academic foundation for consideration for the Innovative Research Award.[4]

Conclusion

Nicusor Iftimia’s academic profile reflects long-term excellence in biomedical optics, precision medicine, and diagnostic innovation. His publication history, citation impact, and interdisciplinary research achievements illustrate continued contributions to scientific advancement and demonstrate the qualities recognized through international research excellence awards.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Nicusor Iftimia, Author ID 6603766089. Scopus. https://www.scopus.com/authid/detail.uri?authorId=6603766089
  2. Iftimia, N., Yadav, P., Primrose, M., Maguluri, G., Jones, J., Grimble, J., & Sheth, R. A. (2026). AI-Assisted OCT Imaging for Core Needle Biopsy Guidance: The 1st in Humans Study. https://doi.org/10.3390/diagnostics16050811
  3. Sampani, K., Mujat, M., Patel, A. H., Kang, C., Iftimia, N., Chatziralli, I., & Sun, J. K. (2024). Characterizing Vascular Wall and Lumen Caliber in Eyes with Diabetic Retinopathy Based on Adaptive Optics Scanning Laser Ophthalmoscopy. https://doi.org/10.3390/diagnostics14182020
  4. Steinberg, R., Meehan, J., Tavrow, D., Maguluri, G., Grimble, J., Primrose, M., & Iftimia, N. (2024). Assessing Lung Fibrosis with ML-Assisted Minimally Invasive OCT Imaging.https://doi.org/10.3390/diagnostics14121243
  5. Maguluri, G., Grimble, J., Mujat, M., Park, J., Caron, A., & Iftimia, N. (2022). Fiber-based hand-held RCM-OCT probe for noninvasive assessment of skin lesions and therapy guidance. https://doi.org/10.1002/tbio.202200002

Mihaela Minea | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Best Researcher Award

Mihaela Minea — Ovidius University of Constanța
Mihaela Minea
Affiliation Ovidius University of Constanța
Country Romania
Scopus ID 58509570100
Documents 65
Citations 67
h-index 4
Subject Area Personalized Medicine
Event International Top Pharmaceutical Awards

Mihaela Minea is associated with Ovidius University of Constanța, Romania, and has contributed to the interdisciplinary field of personalized medicine, rehabilitation sciences, and clinical evaluation methodologies. Her academic profile reflects scholarly engagement in rehabilitation assessment, gait analysis, and evidence-based healthcare approaches relevant to modern pharmaceutical and therapeutic research practices.[1] Her publication activity and citation profile demonstrate continuing participation in applied medical research with emphasis on patient-centered clinical outcomes and rehabilitation innovation.[2]

Abstract

This academic recognition article presents an overview of the scholarly profile and research contributions of Mihaela Minea in the domain of personalized medicine and rehabilitation sciences. Her work includes research on computerized gait analysis, rehabilitation outcomes, and clinical assessment methodologies. The research profile demonstrates involvement in interdisciplinary healthcare research integrating rehabilitation sciences with evidence-based medical evaluation frameworks. The publication record and citation activity indicate continuing academic participation in applied medical and pharmaceutical research relevant to patient-centered healthcare advancement.[1][3]

Keywords

Personalized Medicine, Rehabilitation Sciences, Clinical Research, Gait Analysis, Evidence-Based Medicine, Pharmaceutical Research, Osteoarthritis Rehabilitation, Healthcare Innovation, Medical Assessment, Research Evaluation

Introduction

Personalized medicine has become an important area within modern healthcare systems due to its focus on individualized therapeutic strategies, rehabilitation optimization, and patient-centered clinical interventions. Researchers working in this field contribute to the development of assessment methodologies that improve rehabilitation outcomes and evidence-based healthcare decision-making. Mihaela Minea has participated in research activities related to rehabilitation analysis and clinical outcome assessment, particularly within gait evaluation and osteoarthritis rehabilitation studies.[2] Such investigations support broader advancements in clinical rehabilitation sciences and therapeutic monitoring systems relevant to pharmaceutical and healthcare applications.[4]

Research Profile

The research profile of Mihaela Minea includes scholarly contributions indexed within Scopus author databases and related scientific platforms. Her documented academic activities involve publications associated with rehabilitation medicine, gait analysis technologies, and clinical healthcare evaluation systems.[1] The available citation metrics indicate an active contribution to interdisciplinary medical research with recognized engagement in healthcare-oriented investigations. The combination of publication records, citation activity, and subject specialization demonstrates sustained involvement in patient-focused rehabilitation studies and evidence-driven clinical methodologies.[5]

Research Contributions

The documented research contributions of Mihaela Minea include involvement in studies examining rehabilitation outcomes and computerized gait analysis systems for patients affected by knee osteoarthritis. These studies contribute to the understanding of rehabilitation effectiveness and objective clinical evaluation approaches in musculoskeletal healthcare management.[2] Research activities in rehabilitation sciences are increasingly relevant for modern healthcare systems because they support therapeutic optimization, monitoring strategies, and individualized rehabilitation planning. The integration of digital analysis tools into rehabilitation research also reflects broader trends in precision medicine and data-informed healthcare delivery.[6]

Publications

Selected scientific publications associated with Mihaela Minea demonstrate research interest in rehabilitation science, clinical assessment methodologies, and gait analysis applications in osteoarthritis rehabilitation.[2] These publications contribute to the broader scientific understanding of rehabilitation monitoring and healthcare evaluation systems relevant to personalized therapeutic approaches.[3]

Research Impact

Research impact within rehabilitation sciences is often evaluated through publication indexing, citation activity, and interdisciplinary relevance. The available citation record associated with Mihaela Minea indicates academic recognition within clinical and rehabilitation research communities.[1] Her scholarly work contributes to evidence-based rehabilitation practices and supports continuing discussions regarding digital clinical assessment technologies and patient-centered rehabilitation models. Such contributions are relevant to healthcare professionals, rehabilitation specialists, and medical researchers interested in outcome-oriented therapeutic evaluation systems.[4]

Award Suitability

Mihaela Minea demonstrates suitability for recognition through the Best Researcher Award based on her documented academic contributions, indexed research profile, and participation in rehabilitation and personalized medicine studies. Her scholarly activities align with the objectives of the International Top Pharmaceutical Awards, which recognize meaningful scientific engagement and interdisciplinary healthcare research contributions.[5] The combination of research activity, publication records, and citation visibility supports recognition within professional academic and clinical research environments. Her contributions further reflect continuing efforts toward evidence-based rehabilitation assessment and healthcare innovation.[6]

Conclusion

Mihaela Minea has contributed to the advancement of rehabilitation sciences and personalized medicine through scholarly participation in gait analysis and clinical rehabilitation research. Her academic profile reflects interdisciplinary engagement in evidence-based healthcare methodologies and rehabilitation assessment systems. The indexed research record, citation activity, and continuing relevance of her scientific work support recognition within professional medical and pharmaceutical research communities. These contributions remain relevant to contemporary discussions surrounding patient-centered healthcare, rehabilitation optimization, and digital clinical evaluation technologies.[1][3]

References

  1. Elsevier. (n.d.). Scopus author details: Mihaela Minea, Author ID 58509570100. Scopus.https://www.scopus.com/authid/detail.uri?authorId=58509570100
  2. Minea, M., et al. (2023). Using Computerised Gait Analysis to Assess Changes After Rehabilitation in Knee Osteoarthritis: A Systematic Review and Meta-Analysis of Gait Speed Improvement. Healthcare.DOI: https://doi.org/10.3390/healthcare11050639

Naglaa Shehab | Drug Discovery and Development | Editorial Board Member

Published on by Top Pharmaceutical

Editorial Board Member

Naglaa Shehab — Dubai Medical University
Naglaa Shehab
Affiliation Dubai Medical University
Country United Arab Emirates
Scopus ID 26424069600
Documents 446
Citations 494
h-index 13
Subject Area Drug Discovery and Development
Event International Top Pharmaceutical Awards
ORCID 0000-0002-7514-4055

Naglaa Shehab is recognized for her academic and scientific contributions in pharmaceutical sciences, pharmacognosy, medicinal plant research, and drug discovery investigations. Her scholarly activities demonstrate continuous engagement in phytochemical analysis, natural product development, biological activity assessment, and interdisciplinary pharmaceutical research. Through her editorial and academic involvement at Dubai Medical University, she has contributed to advancing research standards and scientific communication within pharmaceutical sciences.[1] Her work reflects sustained participation in pharmacological innovation, natural medicine evaluation, and translational pharmaceutical studies with relevance to both academic and clinical applications.[2]

Abstract

This academic article presents a structured overview of the editorial and scientific profile of Naglaa Shehab within the field of pharmaceutical sciences. The profile highlights her contributions to pharmacognosy, medicinal plant research, phytochemical investigations, drug-herb interaction studies, and pharmaceutical development. Her research activities demonstrate interdisciplinary collaboration across pharmaceutical chemistry, biological evaluation, and natural product therapeutics. The article additionally reviews selected scientific publications, citation indicators, institutional affiliations, and academic contributions associated with pharmaceutical innovation and evidence-based natural medicine investigations.[1]

Keywords

Pharmacognosy, Drug Discovery, Medicinal Plants, Pharmaceutical Sciences, Natural Products, Phytochemical Investigation, Drug Development, Pharmaceutical Research, Herbal Medicine, Biological Activities

Introduction

Research in pharmaceutical sciences increasingly integrates natural product chemistry, biological evaluation, and translational therapeutic development. Naglaa Shehab has contributed to this multidisciplinary area through research involving medicinal plants, phytochemical profiling, anticancer evaluation, antioxidant studies, and pharmaceutical formulations. Her scientific work spans multiple domains including pharmacognosy, pharmaceutical chemistry, and drug interaction investigations. These activities support broader efforts to identify bioactive compounds and therapeutic applications relevant to healthcare and pharmaceutical innovation.[3]

Research Profile

Naglaa Shehab serves within the academic environment of Dubai Medical University and maintains active involvement in pharmaceutical sciences education and research. Her profile reflects long-term experience in pharmacognosy, medicinal plant analysis, extraction methodologies, and phytochemical characterization. Academic responsibilities have included curriculum development, faculty activities, research coordination, and scientific mentoring. Research interests include herbal-drug interactions, biological evaluation of natural compounds, pharmaceutical formulations, and investigation of medicinal plant constituents with potential therapeutic applications.[1]

  • Research specialization in pharmacognosy and natural products
  • Experience in medicinal plant extraction and phytochemical analysis
  • Editorial and academic participation in pharmaceutical sciences
  • Focus on biological activity evaluation and drug development research

Research Contributions

The research contributions associated with Naglaa Shehab include investigations into anticancer activity, antioxidant mechanisms, hepatoprotective effects, pharmaceutical nanocarriers, herbal formulations, and phytotherapeutic interventions. Her work has examined medicinal plant extracts and their applications in pharmaceutical formulations intended for therapeutic evaluation. Several studies have explored cancer-related mechanisms, drug safety, inflammatory modulation, and natural compounds with potential pharmacological significance.[2][4]

  • Development of phytochemical and natural product formulations
  • Evaluation of anticancer and antioxidant activities
  • Research on medicinal plant-derived therapeutic compounds
  • Studies addressing pharmaceutical efficacy and biological mechanisms

Publications

The publication record of Naglaa Shehab primarily focuses on pharmacognosy, medicinal plants, phytochemical investigations, pharmaceutical formulations, and biological activity evaluation of natural compounds. Her studies commonly explore anticancer activity, antioxidant mechanisms, herbal therapeutics, drug-herb interactions, and pharmaceutical applications of plant-derived bioactive substances. Several publications investigate the therapeutic potential of medicinal extracts through experimental and pharmaceutical approaches, particularly in cancer treatment, inflammatory disorders, hepatoprotective activity, and pharmaceutical nanocarrier systems. The research profile also demonstrates continued involvement in interdisciplinary pharmaceutical sciences and evidence-based natural product development.[3][4]

Research Impact

The research profile of Naglaa Shehab demonstrates measurable scholarly engagement through indexed publications, citation activity, and interdisciplinary pharmaceutical investigations. Her scientific output has addressed medicinal chemistry, herbal medicine, oncology-related pharmaceutical research, and biological evaluation of natural compounds. The documented h-index and citation metrics indicate ongoing academic visibility within pharmaceutical and pharmacognosy-related research communities.[1][5]

Award Suitability

Naglaa Shehab demonstrates suitability for recognition within pharmaceutical and biomedical academic platforms due to her contributions to drug discovery, pharmacognosy, medicinal plant investigations, and pharmaceutical sciences education. Her participation in scientific publishing, interdisciplinary collaborations, and research development aligns with the objectives of international pharmaceutical recognition initiatives. The combination of research productivity, editorial engagement, and pharmaceutical innovation supports her relevance to academic award and editorial board recognition programs.[5]

Conclusion

The academic profile of Naglaa Shehab reflects continued engagement in pharmaceutical sciences, medicinal plant investigations, and natural product research. Her scholarly contributions encompass pharmaceutical formulations, phytochemical analysis, biological evaluation, and interdisciplinary healthcare applications. Through editorial participation, scientific publications, and pharmaceutical research activities, she contributes to ongoing developments within drug discovery and pharmaceutical innovation.[1][2]

References

  1. ORCID. (2026). Naglaa Shehab ORCID profile and academic activities. ORCID Registry.https://orcid.org/0000-0002-7514-4055
  2. Elsevier. (n.d.). Scopus author details: Naglaa Shehab, Author ID 26424069600. Scopus.https://www.scopus.com/authid/detail.uri?authorId=26424069600
  3. Khalifa, A., Shehab, N.G., et al. (2026). Development of Phyllanthus emblica Extract-Loaded Niosomes for Cancer Treatment: Formulation and In Vitro Evaluation. Pharmaceuticals.DOI:https://doi.org/10.3390/ph19040582
  4. Bou Malhab, L.J., Shehab, N.G., et al. (2023). Potential Anticancer Properties of Calotropis procera: An Investigation on Breast and Colon Cancer Cells. Heliyon.DOI:https://doi.org/10.1016/j.heliyon.2023.e16706
  5. Anbar, H.S., El Wakil, A., Shehab, N.G., et al. (2024). The wound healing and hypoglycemic activates of date palm (Phoenix dactylifera) leaf extract and saponins in diabetic and normal rats. PLOS ONE.
    DOI: https://doi.org/10.1371/journal.pone.0308879

Walter Manucha | Nanopharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Best Researcher Award

Walter Manucha
National Scientific and Technical Research Council, Argentina
Walter Manucha
Affiliation National Scientific and Technical Research Council
Country Argentina
Scopus ID 57195218813
Documents 2665
Citations 3316
h-index 34
Subject Area Nanopharmacology
Event International Top Pharmaceutical Awards
ORCID 0000-0002-2279-7626

Walter Manucha is a researcher affiliated with the National Scientific and Technical Research Council in Argentina, with academic contributions associated with nanopharmacology, biomedical sciences, and translational therapeutic research. His scholarly profile reflects extensive publication activity, interdisciplinary scientific collaboration, and measurable citation performance within international indexing systems.[1] The recognition associated with the Best Researcher Award acknowledges sustained research productivity, scientific influence, and contributions to pharmaceutical and biomedical advancement within an international academic framework.[2]

Abstract

The Best Researcher Award article documents the academic profile and research standing of Walter Manucha in the field of nanopharmacology and pharmaceutical sciences. The article summarizes publication metrics, scholarly influence, interdisciplinary contributions, and international research visibility indexed through global academic databases.[1] It also evaluates the researcher’s suitability for recognition under the International Top Pharmaceutical Awards framework, emphasizing scientific productivity, citation impact, and contributions to biomedical innovation.[2]

Keywords

Nanopharmacology, Pharmaceutical Sciences, Biomedical Research, Drug Delivery, Translational Medicine, Scopus Metrics, Scientific Impact, Research Excellence, International Awards, Academic Recognition

Introduction

Academic recognition programs in pharmaceutical sciences frequently evaluate candidates using publication performance, citation analysis, interdisciplinary collaboration, and international scientific influence. Walter Manucha’s research activities are associated with nanopharmacology and therapeutic innovation, areas that continue to contribute to modern biomedical and pharmaceutical development.[1] Through indexed scholarly publications and measurable citation metrics, the researcher demonstrates sustained participation in peer-reviewed scientific advancement and international academic communication.[3]

Research Profile

Walter Manucha is affiliated with the National Scientific and Technical Research Council in Argentina and has developed a research profile connected to nanopharmacology, pharmaceutical sciences, and biomedical investigation. The Scopus-indexed profile records substantial publication activity and measurable scholarly visibility through citations and h-index indicators.[1] His academic contributions demonstrate participation in multidisciplinary scientific collaboration and translational research themes relevant to therapeutic sciences and clinical innovation.[4]

  • Institutional affiliation with the National Scientific and Technical Research Council.
  • Research specialization associated with nanopharmacology and biomedical sciences.
  • Scopus-indexed publication and citation visibility.
  • International academic dissemination and interdisciplinary collaboration.

Research Contributions

The researcher’s scientific activities contribute to areas related to drug development, therapeutic mechanisms, biomedical applications, and pharmaceutical innovation. Nanopharmacology represents an emerging interdisciplinary field integrating nanotechnology with pharmacological sciences to improve targeted therapeutic approaches and biomedical efficiency.[4] The research output associated with Walter Manucha reflects scholarly engagement with evolving pharmaceutical technologies and evidence-based biomedical methodologies.[5]

  • Development of interdisciplinary biomedical research frameworks.
  • Contributions to therapeutic and pharmaceutical sciences.
  • Scientific dissemination through indexed journal publications.
  • Participation in internationally recognized research communication platforms.

Publications

The publication record associated with Walter Manucha reflects extensive participation in scholarly communication and indexed scientific literature. Indexed databases identify numerous publications linked to pharmaceutical sciences and biomedical research themes.[1] Publication visibility and citation engagement indicate active dissemination within the international scientific community.[3]

  1. Research articles in nanopharmacology and biomedical sciences.
  2. Peer-reviewed publications indexed in international databases.
  3. Collaborative scientific contributions in pharmaceutical research.
  4. Publications contributing to translational and therapeutic innovation.

Research Impact

Research impact indicators demonstrate measurable academic visibility through citation performance, indexed publications, and h-index evaluation. Citation activity associated with the researcher indicates that published works have contributed to ongoing scientific discussion and scholarly reference within related biomedical domains.[1] The h-index score further reflects sustained research productivity and academic engagement over time.[3]

  • Scopus-indexed visibility and citation accumulation.
  • Sustained publication activity within pharmaceutical sciences.
  • Research dissemination through international scholarly networks.
  • Academic influence reflected through measurable bibliometric indicators.

Award Suitability

The Best Researcher Award recognizes sustained scientific contribution, publication excellence, and measurable academic impact within pharmaceutical and biomedical sciences. Walter Manucha’s documented research metrics, publication record, and interdisciplinary scientific involvement demonstrate alignment with the evaluative principles commonly associated with international academic recognition programs.[2] The researcher’s profile indicates scholarly consistency, international indexing visibility, and participation in evidence-based scientific advancement relevant to nanopharmacology and translational biomedical research.[5]

Conclusion

Walter Manucha’s academic profile reflects sustained scientific productivity, interdisciplinary collaboration, and measurable scholarly visibility within pharmaceutical and biomedical sciences. Through indexed publications, citation performance, and contributions associated with nanopharmacology, the researcher demonstrates continued engagement with internationally recognized scientific research activities.[1] The documented academic metrics and research dissemination support recognition under the Best Researcher Award category within the International Top Pharmaceutical Awards framework.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Walter Manucha, Author ID 57195218813. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57195218813
  2. International Top Pharmaceutical Awards. (n.d.). Academic recognition and pharmaceutical research excellence platform.
    https://toppharmaceutical.org/
  3. Martín Gimenez, V. M., García Menendez, S., & Manucha, W. (2026). Multi-endogenous nanoformulation for endocannabinoid and hormonal modulation of key signaling pathways in resistant hypertension. Current Pharmaceutical Design.
    https://doi.org/10.2174/0113816128396666250728074858
  4. Reiter, R. J., Sharma, R., Loh, D., Chuffa, L. G. A., Bai, Y., Zuccari, D. A. P. C., Galano, A., & Manucha, W. (2026). Melatonin targets mitochondrial redox homeostasis: Optimizing the intracellular microenvironment. International Journal of Molecular Sciences.
    https://doi.org/10.3390/ijms27104496
  5. Carloni, S., Luchetti, F., Nasoni, M. G., Balduini, W., Manucha, W., & Reiter, R. J. (2026). Melatonin and mitochondrial stress: New insights into age-related neurodegeneration. Neural Regeneration Research.
    https://doi.org/10.4103/NRR.NRR-D-24-01380

Aniela Montserrat Silva Nolasco | Pharmaceutical Chemistry | Excellence in Research Award

Published on by Top Pharmaceutical

Excellence in Research Award


Aniela Montserrat Silva Nolasco

Universidad de Castilla-La Mancha, Spain


Aniela Montserrat Silva Nolasco
Affiliation Universidad de Castilla-La Mancha
Country Spain
Scopus ID
57221107566
Documents 21
Citations 23
h-index 2
Subject Area Pharmaceutical Chemistry
Event International Top Pharmaceutical Awards

Aniela Montserrat Silva Nolasco is a pharmaceutical science researcher associated with Universidad de Castilla-La Mancha, Spain. Her academic profile demonstrates research engagement in molecular pharmacology, pharmaceutical chemistry, cancer biology, and bioactive therapeutic compounds. Published studies associated with her scholarly work examine anticancer properties of argentatins, immunomodulatory activity, and translational therapeutic applications in oncology-related biomedical sciences.[1] Her research contributions are indexed through recognized academic databases including Scopus and ORCID, supporting international visibility and scientific dissemination within pharmaceutical and biomedical research communities.[2]

Abstract

This article summarizes the academic contributions and pharmaceutical research activities of Aniela Montserrat Silva Nolasco. The profile reflects scholarly involvement in cancer biology, molecular pharmacology, pharmaceutical chemistry, and translational therapeutic research involving argentatin compounds and related bioactive agents.[3] Indexed publications, DOI-linked research outputs, and collaborative scientific studies contribute to the researcher’s academic visibility within pharmaceutical and biomedical sciences.[4]

Keywords

Pharmaceutical Chemistry, Molecular Pharmacology, Anticancer Research, Argentatins, Cancer Biology, Translational Medicine, Immunomodulation, Biomedical Sciences, Oncology Research, Therapeutic Compounds.

Introduction

Pharmaceutical research associated with molecular therapeutics and cancer-related biomedical investigations continues to contribute substantially to contemporary translational medicine. Current scientific developments increasingly emphasize naturally derived compounds with potential therapeutic applications against tumor progression and immune dysregulation.[5] Research contributions associated with Aniela Montserrat Silva Nolasco demonstrate participation in this evolving pharmaceutical research landscape through investigations involving argentatins and cellular pharmacological mechanisms.[6]

Research Profile

The academic profile of Aniela Montserrat Silva Nolasco includes affiliations with Universidad de Castilla-La Mancha and previous research and educational activities associated with pharmaceutical and molecular sciences. Her scholarly background includes pharmaceutical biology, cellular pharmacology, and laboratory-based biomedical investigations relevant to therapeutic development and oncology-focused pharmaceutical sciences.[2]

The Scopus profile linked to the researcher identifies indexed publication activity, citation tracking, and collaborative research participation within pharmaceutical and biomedical disciplines. These indicators support measurable academic visibility and ongoing scholarly communication across internationally indexed scientific platforms.[1]

Research Contributions

Research contributions associated with Aniela Montserrat Silva Nolasco include investigations on argentatin compounds and their biological activity in cancer-related cellular environments. Published studies report antimigratory and antiangiogenic effects alongside analyses of long-term resistance induction associated with argentatin A and argentatin B.[3]

Additional scientific contributions address immunomodulatory activity isolated from guayule-derived compounds and synergistic therapeutic interactions involving 5-fluorouracil in colorectal cancer cell models. These studies contribute to broader translational pharmaceutical research exploring molecular therapeutic strategies in oncology-related biomedical sciences.[4]

Publications

The publication profile associated with Aniela Montserrat Silva Nolasco includes peer-reviewed research outputs indexed through recognized scientific databases. DOI-linked publications contribute to scholarly accessibility, research transparency, and international academic dissemination within pharmaceutical chemistry and molecular biomedical sciences.[3][4]

DOI-linked publications facilitate long-term accessibility and citation reliability within digital academic infrastructures. The use of persistent identifiers further supports research transparency, discoverability, and scholarly preservation across multidisciplinary scientific environments.[3]

Research Impact

Research impact is commonly evaluated using publication visibility, citation performance, indexed dissemination, and scholarly engagement across scientific communities. The researcher’s profile demonstrates documented participation in peer-reviewed pharmaceutical and biomedical research activities through Scopus-indexed publications and DOI-associated scholarly outputs.[1]

The available citation indicators and publication metrics support measurable academic relevance within specialized pharmaceutical chemistry and translational biomedical research domains. Continued scientific dissemination and collaborative publication activity may further strengthen long-term academic visibility and research influence.[2]

Award Suitability

The research activities and scholarly outputs associated with Aniela Montserrat Silva Nolasco align with the objectives of the International Top Pharmaceutical Awards through contributions to pharmaceutical chemistry, cancer-related therapeutic investigations, and molecular biomedical sciences.[6] The profile reflects participation in interdisciplinary scientific studies relevant to pharmaceutical innovation and translational therapeutic development.[3]

Conclusion

Aniela Montserrat Silva Nolasco has contributed to pharmaceutical and biomedical research through studies involving anticancer compounds, immunomodulatory activity, and molecular therapeutic investigations. Her academic profile demonstrates scholarly engagement within pharmaceutical chemistry and translational medicine, supported by indexed publications, collaborative research contributions, and DOI-linked scientific dissemination.[5]

References

  1. Elsevier. (n.d.). Scopus author details: Aniela Montserrat Silva Nolasco, Author ID 57221107566. Scopus.https://www.scopus.com/authid/detail.uri?authorId=57221107566
  2. ORCID. (2026). Aniela M. Silva-Nolasco ORCID profile, affiliations, and academic activities.https://orcid.org/0000-0002-2134-7551
  3. Silva-Nolasco, A. M., Galvez, B. G., de la Cruz-Morcillo, M. A., & Carmona, M. (2026). Differential anti-cancer effects of argentatin A and B: antimigratory, antiangiogenic, and long-term resistance induction. Industrial Crops and Products.https://doi.org/10.1016/j.indcrop.2026.123255
  4. Silva-Nolasco, A. M., Singh, N., de la Cruz-Morcillo, M. A., García-Martínez, M. M., Zalacain, A., Gálvez, B. G., & Carmona, M. (2024). Immunomodulatory activity of argentatins A and B isolated from guayule. PLOS ONE.https://doi.org/10.1371/journal.pone.0304713
  5. Sánchez‐Olivares, P., Silva‐Nolasco, A. M., de la Cruz‐Morcillo, M. A., García‐Martínez, M. M., Pinedo‐Serrano, A., Carmona, M., & Galán‐Moya, E. M. (2024). Synergistic Potential of Argentatins A and B to Improve 5‐Fluorouracil Cytotoxicity in Colorectal Cancer Cell Models. Journal of Cellular and Molecular Medicine.https://doi.org/10.1111/jcmm.70294

Shanshan Guo | Pharmacology | Research Excellence Award

Published on by Top Pharmaceutical

Dr. Shanshan Guo | Pharmacology | Research Excellence Award

Principal Investigator | China Academy of Chinese Medical Sciences | China

Dr. Shanshan Guo is a Principal Investigator and Director at the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, specializing in pharmacology and integrative medicine with a focus on Chinese materia medica and respiratory diseases. She holds advanced degrees in traditional Chinese medicine, integrated Chinese and Western medicine, and pharmacology, reflecting a strong interdisciplinary academic foundation. Her professional career demonstrates progressive leadership, including roles as Principal Investigator and research lead, where she has directed major pharmacological research initiatives and innovative experimental platforms. Her research centers on antiviral therapeutics, mechanisms of pathogen-host interaction, and safety evaluation of traditional Chinese medicine, supported by extensive publications and impactful contributions to translational medicine. She has successfully led funded projects on broad-spectrum antiviral agents and pharmacodynamic mechanisms of herbal formulations, highlighting her scientific rigor and innovation. Dr. Guo’s work has earned recognition through competitive research funding, leadership responsibilities, and contributions to advancing evidence-based integration of traditional and modern medicine, positioning her as a significant contributor to global pharmaceutical and biomedical research.

Citation Metrics (Google Scholar)

745
560
375
190
0

745

116

15

Citations

Documents

h-index


Top 5 Featured Publications